Policy submissions
SHPA is committed to promoting best practice medicines management and fostering a greater understanding and appreciation of the key role hospital pharmacists, and pharmacists working in other healthcare settings, play in delivering evidence-based healthcare.
We utilise the evidence generated by research, the clinical leadership of SHPA’s Specialty Practice Committees and Reference Groups, and the expertise of members who provide quality healthcare at the coalface, to provide advice and input into policy development at federal and jurisdictional levels.
Reflecting members’ diverse and innovative roles, SHPA has a comprehensive understanding of the multiple funding and regulatory frameworks with respect to medicines and welcomes the opportunity to engage with governments and other stakeholders.
Policy submissions
SHPA develops submissions to government and stakeholder consultations which express SHPA’s positions on important issues that have the potential to impact medicines management, access to medicines and the well-being of Australian consumers.
May
- SHPA's Tasmania Branch Committee Submission to Long-Term Plan for Healthcare in Tasmania in 2040
- SHPA response to the Australian Pharmacy Council's Accreditation Standards for Aged Care and Medication Management Review (MMR) Pharmacist Training Programs
- SHPA submission to Targeted Consultation for Proposed Amendments to Drugs, Poisons and Controlled Substances Regulations 2017
- SHPA submission to Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard Consultation
- SHPA submission to Inquiry: Improving Access to Medicinal Cannabis Bill 2023
- SHPA SA/NT Branch Committee submission to South Australia’s Palliative Care Services Plan and Model of Care Framework
April
- SHPA ACT Branch Committee submission to voluntary assisted dying in the ACT consultation
- SHPA's response to Accreditation Standards for pharmacist prescriber education programs
March
- SHPA’s Victoria Branch Committee submission to DPCS Amendment Regulations 2023
- SHPA response to Therapeutic Goods Recall Processes - Seeking Feedback on Improvements to the Recalls Process
- SHPA response to Inquiry: Access to Urinary Tract Infection Treatment in South Australia
- SHPA response to PSA Professional Practice Standards Consultation
February
- SHPA response to How AHPRA and the National Boards propose to use the new power to issue public statements (warnings)
- SHPA Queensland Branch Committee response to QScript Mandatory Checking Consultation
- SHPA Queensland Branch Committee response to Queensland Health Monitored Medicines Standard compliance
- SHPA response to Review of accreditation arrangements to prepare for 2024-2029 cycle
- SHPA response to Public consultation on proposed amendments to the Poisons Standard - ACMS, ACCS & Joint ACMS-ACCS, March 2023 - Substance 1 Celecoxib
- SHPA submission to public consultation on items to be considered by the PBAC
January
- SHPA provided feedback to Victorian DPCS Regulations 2017 – transmission of a digital image of a paper prescription in an emergency - December 2022
- SHPA provides feedback to the TGA on the International Harmonisation of Ingredient Names (IHIN) Dual labelling transition to sole medicine ingredient names consultation - December 2022
- SHPA response to Australian Cancer Plan 2023-2033 - December 2022
- SHPA response to Universal Access to Reproductive Healthcare - December 2022
- SHPA provides feedback on the Revised PBS Post-market Review (PMR) Framework - December 2022
- SHPA response to Universal Access to Reproductive Healthcare - December 2022
- Qld Branch Committee response to Queensland Health Workforce Strategy - November 2022
- SHPA response to discussion paper: new program for in-home aged care - November 2022
- SHPA response to Consultation – Review of the Aged Care Quality Standards: Standard 5, Clinical Care - November 2022
- SHPA provides feedback to the South Australian Cancer Plan - November 2022
- SHPA response to Inquiry into Long COVID and Repeated COVID Infections - November 2022
- SHPA’s Response to the Efficient Funding of Chemotherapy (EFC) Review Interim Report - October 2022
- SHPA ACT Branch Committee Submission to the Draft ACT Drug Strategy Action Plan 2022-2026 - October 2022
- SHPA Victoria Branch Committee response to Health Workforce Strategy Victoria - October 2022
- SHPA Tasmanian Branch Committee Submission to Tasmanian Budget 2022-2023 consultation - October 2022
- SHPA response to WA Amendments to the Medicines and Poisons Regulations 2016 and the Schedule 8 Medicines Prescribing Code - October
- SHPA response to Product Information as a package insert in boxed injectables - October
- SHPA response to Proposed amendments to the Poisons Standard – ACCS, ACMS and joint ACCS/ACMS November 2022 meetings (ivermectin) - September
- SHPA feedback to revised draft National Medicines Policy consultation - September
- SHPA ACT Branch Committee Submission to the ACT Health Workforce Sustainability Strategy 2022-2032 - September
- SHPA NSW Branch Committee response to Inquiry into Impact of ambulance ramping and access block on the operation of hospital emergency departments in New South Wales - September
- SHPA NSW Branch Committee submission to Clinical Practice Guide Review: Use of SGLT2-inhibitor medicines for people with type 2 diabetes receiving acute inpatient care - September
- SHPA Submission to the Aged care on-site pharmacist measure - September
- SHPA response to Improving medication management in residential aged care (VIC) via survey - August
- SHPA submission to Allied Health Mental Health Early Career Program Requirements for Smaller and Emerging Disciplines (VIC) - August
- SHPA submission to Proposal to restrict permits for Schedule 9 poisons for human therapeutic use under the Drugs, Poisons and Controlled Substances Regulations 2017 to clinical trials approved by a human research ethics committee - August
- ACT Branch Submission to Medicine Authorisations - August
- SHPA submission to NSW Regional Health Plan Consultation - July
- SHPA Tasmanian Branch submission to Our Healthcare Future: Advancing Tasmania’s Health (Exposure Draft) - July
- SHPA Submission to Consultation Paper on the Pricing Framework for Australian Public Hospital Services 2023–24 - July
- SHPA NSW Branch Committees submission to the NSW Health Draft revised policy: Approval Process of Medicines and Their Use - July
- SHPA Consultative Submission on the Draft Voluntary Assisted Dying Regulation 2022 (Qld) - June
- SHPA NSW Branch Submission on the Draft Medicines, Poisons and Therapeutic Goods Bill 2022 (NSW) - June
- SHPA ACT Branch submission to the ACT Budget 2022-2023 consultation – June
- SHPA response to Maintaining and improving transparency of medicine adverse event information on the TGA – April
- SHPA submission to TGA Repurposing follow-up consultation – April
- SHPA response to Opioid Deprescribing Guideline – April
- SHPA submission to Review of Pharmaceutical Reform Agreements – March
- SHPA submission to Inquiry into Childhood Rheumatic Diseases – March
- SHPA response to The Australian Cancer Plan 2023-2033 Consultation – March
- SHPA Tas Branch response to Tasmanian Voluntary Assisted Dying Consultation and Information Paper – Hospital Pharmacists – March
- SHPA Submission on the Consultation Draft – National Medicines Policy – March
- SHPA response to the National Medicines Traceability Framework Consultation – March
- SHPA submission to the Review and Revision of the National Alcohol and Other Drug Workforce Development Strategy – March
- SHPA response to TGA consultation on Extemporaneous Compounding of Emergency Medicines: Proposal to improve patient access to critical medicines in acute-care settings – February
- SHPA NSW Branch submission to NSW Budget 2022–2023 consultation – February
- SHPA Pre-Budget Submission 2022-23 – January
- WA Branch Submission to the Western Australian Health Networks Consultation Re: The Hospital Stay Guideline for Hospitals and Disability Service Organisations via online survey – January
- SHPA Submission to consultation on National Quality Use of Medicines Publication Guiding principles to achieve continuity in medication management – December 2021
- SHPA Tasmanian Budget Community Consultation Submission 2022-2023 – December
- SHPA’s Response to the Review of the National Medicines Policy (NMP) Discussion Paper 2021 – November
- SHPA conditional endorsement of Acute Anaphylaxis CCS – October
- SHPA feedback on ACSQHC National Medication Management Plan User Guide – October
- SHPA SA/NT Branch submission Public Consultation on amendments to mandate the use of ScriptCheckSA – October
- SHPA response to TGA Interim decisions to amend (or not amend) the current Poisons Standard (oral contraceptive substances) – October
- SHPA response to the Post-Market Review of Opiate Dependence Treatment Program Medicines – October
- SHPA submission to Senate Inquiry on Provision of general practitioner and related primary health services to outer metropolitan rural and regional Australians – October
- SHPA’s response to the draft Opioid Analgesic Stewardship in Acute Pain Clinical Care Standard – October
- SHPA response to the draft Guiding principles for the governance of high-cost medicines in Australian hospitals – October
- SHPA response to the Draft Sepsis Clinical Care Standard Consultation – October
- SHPA response to the National QUM Publication - Guiding Principles for medication management in the community – September
- SHPA response to the National QUM Publication - Guiding Principles for medication management in RACF – September
- SHPA's response to the draft National Mental Health Workforce Strategy – September
- SHPA response to the TGA's Proposed changes to the Required Advisory Statements Medicine Labels for a range of medications – September
- SHPA response to TGA Improving access to life-saving unapproved medicines via the Special Access Scheme Category A pathway in emergency situations – September
- SHPA submission to the Department of Health re draft ToR for Pharmaceutical Reform Agreements review – September
- SHPA response to the Victorian Antimicrobial Resistance Strategy consultation – September
- SHPA Vic Branch submission to draft Victorian Pharmacy Authority Standards – August
- SHPA response to Vic Department of Health RE new Mental Health and Wellbeing Act – August
- SHPA letter re draft consent forms and proposed FAQs for DAAs in the new Commonwealth Programs – July
- SHPA response to the Review of the Efficient Funding of Chemotherapy (EFC) program Discussion Paper – July
- SHPA submission RE draft Palliative Care Strategic Framework 2021-2026 – July
- SHPA Submission re ACT 2021–2022 budget consultation – July
- SHPA response to PBS draft TOR on the post-market review of medicines available under the PBS Opiate Dependence Treatment Program – June
- SHPA submission to the Commission on the National Opioid Analgesic Stewardship Program – June
- SHPA provides feedback to the TGA’s consultation on Building a more robust medicine supply – May
- SHPA provides feedback to the TGA on the Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Lidocaine (lignocaine) – May
- SHPA provides feedback to the TGA on the Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistamines – May
- SHPA Qld Branch submission to QAIHC Making tracks towards health equity – April
- SHPA response to consultation on draft National Preventative Health Strategy – April
- SHPA provides input to the 2021–2022 Tasmanian Government budget consultation process – April
- SHPA provides feedback to TGA on TGO 110 Standard for Vaporiser Nicotine – April
- Submission to TGA consultation on Repurposing of Prescription Medicines via online survey – March
- SHPA ACT Branch letter to the ACT Chief Health Officer regarding Real Time Notifications and Alerts – March
- SHPA Tasmania Branch provides feedback to the Tasmanian Department of Health real time prescription monitoring consultation – February
- SHPA feedback to SkillsIQ RE Draft 2 Cert III and Cert IV in Hospital Services Pharmacy Support – February
- SHPA Vic Branch submission to the Victorian Department of Health’s COVID-19 Vaccination Preparedness Unit – February
- SHPA Submission to Inquiry into Health outcomes & access to health & hospital services in rural, regional and remote NSW – January
- SHPA feedback to the TGA’s consultation on the revision of ‘Compounded medicines and good manufacturing practice (GMP) – Guide to the interpretation of the PIC/S guide to GMP for compounded medicinal products’ – December
- SHPA Submission to the Royal Commission into Aged Care – Counsel Assisting – December
- SHPA response to Indigenous Dose Administration Aids Program: Discussion Paper – November
- SHPA submission to AIHW Consultation on the National Palliative Care and End-of-Life Care Information Priorities – November
- SHPA feedback to TGA on the interim decision in relation to nicotine – November
- SHPA submission to Department of Health on Review of the My Health Record legislation – October
- SHPA Submission to the Quality Use of Medicines and Medicines Safety (10th National Health Priority) – Phase 1: Aged Care – October
- SHPA Qld Branch response to Qld Health inquiry into the establishment of a pharmacy council and transfer of pharmacy ownership in Qld – September
- Submission to NPS on Prescribing Competencies Framework – September
- SHPA's feedback to the TGA on the Therapeutic Goods Order 106 – Data Matrix codes and serialisation of medicines (TGO 106) – August
- SHPA feedback to SkillsIQ RE Cert III and Cert IV in Hospital Services Pharmacy Support – August
- SHPA’s submission to SA Health re pharmacist supply under a TGA SSMS notice – August
- SHPA's feedback to the ACT inquiry into the COVID-19 response – August
- SHPA's feedback to the Queensland inquiry into the COVID-19 response – August
- SHPA's feedback to the South Australian inquiry into the COVID-19 response – August
- SHPA's feedback to the Victorian inquiry into the COVID-19 response – August
- SHPA submission to the Department of Health – National Injury Prevention Strategy–2030 – July
- SHPA submission to Senate Inquiry into the Australian Government’s response to the COVID-19 pandemic – June
- SHPA feedback on the PBS post-market review of medicines for smoking cessation – May
- SHPA South Australian Branch’s response to Electronic Prescribing in South Australia – April
- SHPA feedback on TGA Amendments to the Poisons Standard – February
- SHPA submission to Aged Care Program Redesign Consultation – February
- SHPA submission to the Senate inquiry into current barriers to patient access to medicinal cannabis in Australia – January
Other submissions
- SHPA submission to the Royal Commission into Aged Care Quality and Safety – June 2019
- SHPA submission to the 2018–2019 Federal Budget – December 2017
Advocacy publications
- Reducing opioid-related harm: A hospital pharmacy landscape paper for the Medicines Leadership Forum, July 2018
For more information about SHPA’s policy work, contact Jerry Yik, Head of Policy and Advocacy.